Hepatitis B Genotypes and Response to Antiviral Therapy: A Review

@article{Palumbo2007HepatitisBG,
  title={Hepatitis B Genotypes and Response to Antiviral Therapy: A Review},
  author={Emilio Palumbo},
  journal={American Journal of Therapeutics},
  year={2007},
  volume={14},
  pages={306-309}
}
  • E. Palumbo
  • Published 1 May 2007
  • Biology, Medicine
  • American Journal of Therapeutics
The aim of this review is to examine the impact of hepatitis B virus (HBV) genotypes on biochemical and virologic response to antiviral drugs (alfa-interferon and pegylated-interferon alfa-2b, lamivudine, and adefovir dipivoxil) actually used for the treatment of chronic hepatitis, HBV related. International literature evidences that HBV genotypes D and C are associated with a lower rate of favorable response to alfa-interferon and pegylated-interferon alfa-2b therapy than genotypes A and B… 
Effect of Hepatitis B Virus Genotypes on the Efficacy of Adefovir Dipivoxil Antiviral Therapy
TLDR
HBV genotypes B and C have no significant difference in virologic, biochemical, and immunologic response to ADV, the most popular antiviral drug in China due to its low price, good antiviral efficacy, few side effects, and convenient of administration.
HBV Genotype B/C and Response to Lamivudine Therapy: A Systematic Review
A number of nucleoside analogues such as lamivudine (LAM), actually used for the treatment of chronic hepatitis B, can suppress HBV DNA replication, improve transaminase level and liver histology,
Hepatitis B Virus Genotyping Among Chronic Hepatitis B Individuals With Resistance to Lamivudine in Shahrekord, Iran
TLDR
In addition to genotype D, other lamivudine resistant hepatitis B genotypes might be distributed in Iran, and this is the first report on isolation of Genotype C from Iran.
Hepatitis B virus genotypes and lamivudine resistance mutations in Jordan.
TLDR
HBV genotype D appears to be the only circulating type in Jordanian patients and a relatively low prevalence of HBeAg expression among examined cases might help in the formulation of management plans and for predicting clinical outcomes.
Clinical course of chronic hepatitis B patients receiving nucleos(t)ide analogues after virological breakthrough during monotherapy with lamivudine.
TLDR
It is shown that baseline serum HBV DNA is an important predictor of virologic response and thatVirologic breakthrough is significantly associated with the insurgence of genotypic resistance.
Does genotype predict response to treatment in children infected with hepatitis B perinatally?
TLDR
The response to treatment by genotype should be evaluated in future clinical trials in children and assessment of genotype in children pre‐treatment may provide a guide to potential response.
Association between clinical features and YMDD mutations in patients with chronic hepatitis B following lamivudine therapy.
TLDR
Results indicate that one year of LAM therapy is able to improve ALT normalization and may induce YMDD mutation and drug resistance in chronic hepatitis B patients after lamivudine (LAM) therapy.
Long Term Effects of Lamivudine and Adefovir dipivoxil in Chronic Hepatitis B Patients on the Development of Hepatocellular Carcinoma
TLDR
With hepatitis B immunization and effective antiviral therapy, global control of HBV infection and HBV-related complications, including HCC, are possible by the end of the first half of the century.
Variables determining the virologic response to adefovir treatment in patients with chronic HBV infection previously treated with lamivudine
TLDR
It was suggested that adefovir was more effective in HBeAg negative patients, and was more rational to continue the treatment in patients who had a decrease of at least 2log10units in serum HBV DNA levels at 6th month of treatment.
Variability in the Responses of Hepatitis B Virus D-Subgenotypes to Antiviral Therapy: Designing Pan-D-Subgenotypic Reverse Transcriptase Inhibitors
TLDR
This study investigated the effectiveness of ETV/TDF on HBV/D-subgenotypes, studied the structural/functional differences in subgenotype-specific reverse transcriptase (RT) domains of viral polymerase, and identified novel molecules with robust inhibitory activity on various D- Subgenotypes.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 33 REFERENCES
Hepatitis B virus genotypes and response to antiviral therapy.
TLDR
Determining the genotype could be helpful for predicting the outcome of antiviral therapy in patients with chronic hepatitis B, and virological response is worse during lamivudine therapy, and is also less durable after the discontinuation of therapy than in Patients with genotype B infection.
Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.
TLDR
There was no difference in the antiviral response and the rate of development of YMDD mutations in Chinese patients with genotype B and C after 1 year of lamivudine.
Response to interferon alfa is hepatitis B virus genotype dependent: genotype A is more sensitive to interferon than genotype D.
TLDR
HBV genotypes A and D are important and independent predictors of IFN responsiveness in chronic hepatitis B and HBV genotype adapted treatment regimens may further improve treatment efficacy in Chronic hepatitis B.
Is HBV genotyping of clinical relevance?
TLDR
HBV genotypes clearly are found to be different in various geographical areas of infection, whereas in Asian patients genotypes B and C are more frequent, and in the Middle-East the genotype D is more frequent.
Influence of hepatitis B virus genotypes on the progression of chronic type B liver disease
TLDR
Although the patients with genotype B experience earlier HBe seroconversion, slower progression of liver fibrosis, and slower development of HCC, the life‐long risk of progression to advanced fibrosis and development ofHCC may not differ among genotypes B‐ and C‐related chronic liver disease.
Significance of hepatitis B genotype in acute exacerbation, HBeAg seroconversion, cirrhosis‐related complications, and hepatocellular carcinoma
TLDR
Although patients with genotype B had earlier HBeAg seroconversion, there was no significant reduction in the risk of development of complications and HBV genotypes B and C are associated with high prevalence of precore and core promoter mutations, respectively.
Hepatitis B virus genotype has no impact on hepatitis B e antigen seroconversion after lamivudine treatment
TLDR
HBeAg seroconversion after treatment by lamivudine was not influenced by the HBV genotype, and it was found that loss of HBeAg, appearance of anti-HBe and normalization of alanine aminotransferase for at least 6 months was normalized.
Hepatitis B Virus Genotype D Prevails in Patients with Persistently Elevated or Normal ALT Levels in Turkey
TLDR
Genotype D is the predominant type among hepatitis B carriers residing in the authors' region and is not associated with more severe liver diseases, however, additional large-scale longitudinal studies are needed to find the relationship of HBV genotypes to liver disease severity and clinical outcomes.
...
1
2
3
4
...